Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Diagnostic or test agent produces in vivo fluorescence
Reexamination Certificate
2006-10-24
2006-10-24
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Diagnostic or test agent produces in vivo fluorescence
C514S184000, C514S410000, C514S453000, C514S454000, C424S145100, C424S184100
Reexamination Certificate
active
07125542
ABSTRACT:
Provided are methods and compositions for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-angiogenesis factor, for example, angiostatin or endostatin, or with an apoptosis-modulating factor. Furthermore, the selectivity and sensitivity of the PDT may be further enhanced by coupling a targeting moiety to the photosensitizer so as to target the photosensitizer to choroidal neovasculature.
REFERENCES:
patent: 5171749 (1992-12-01), Levy et al.
patent: 5707986 (1998-01-01), Miller et al.
patent: 5733876 (1998-03-01), O'Reilly et al.
patent: 5798349 (1998-08-01), Levy et al.
patent: 5854205 (1998-12-01), O'Reilly et al.
patent: 6117862 (2000-09-01), Margaron et al.
patent: 6162242 (2000-12-01), Peyman et al.
patent: 6180402 (2001-01-01), Granville et al.
patent: 6225303 (2001-05-01), Miller et al.
patent: 6270749 (2001-08-01), Blumenkranz et al.
patent: 6331523 (2001-12-01), Kljavin et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6899723 (2005-05-01), Chen
patent: 2002/0049247 (2002-04-01), Chen
patent: 2003/0171320 (2003-09-01), Guyer et al.
patent: 2003/0175282 (2003-09-01), Miller et al.
patent: 2003/0185834 (2003-10-01), Miller et al.
patent: 2004/0167091 (2004-08-01), Guyer et al.
patent: 2005/0043220 (2005-02-01), Guyer et al.
patent: WO 95 24930 (1995-09-01), None
patent: WO 97/05127 (1997-02-01), None
patent: WO 97 33619 (1997-09-01), None
patent: WO 97 45450 (1997-12-01), None
patent: WO 98 25648 (1998-06-01), None
patent: WO 99 03503 (1999-01-01), None
patent: WO 00/40089 (2000-07-01), None
patent: WO 00 51638 (2000-09-01), None
patent: WO 01 51087 (2001-07-01), None
patent: WO 01/58240 (2001-08-01), None
patent: WO 03/039404 (2003-05-01), None
Verma et al., Nature 389: 239-242, Sep. 1997.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Adamis et al, Arch Ophthalmol 114(1): 66-71, Jan. 1996.
Kramer et al, Ophthalmology 103(3): 427-38, Mar. 1996.
Adamis et al. “Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia—Associated Iris Neovascularization in a Nonhuman Primate” (1996)Arch Ophthalmol,vol. 114, pp. 66-71.
Ahmad et al “Photodynamic Therapy Results in Induction of WAF1/C1P1/P21 Leading to Cell Cycle Arrest and Apoptosis” (1998)Proc. Natl. Acad. Sci. USA,vol. 95, pp. 6977-6982.
Allen et al. “Photodynamic Therapy: Tumor Targeting with Adenoviral Proteins” (1999)Photochemistry and Photobiology,vol. 70, No. 4, pp. 512-523.
Akhlynina et al. “Insulin-mediated Intracellular Targeting Enhances the Photodynamic Activity of Chlorine6” (1995)Cancer Research,vol. 55, pp. 1014-1019.
Arenberg et al.“Interferon-y-inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Canter (NSCLC) Tumorigenesis and Spontaneous Metastases” (1996)J. Exp. Med.vol. 184, pp. 981-992.
Ball et al. “A Comparative Study of the Cellular Uptake and Photodynamic Efficacy of Three Novel Zinc Phthalocyanines of Differing Charge” (1999)Photochemistry and Photobiology,vol. 69, No.3, pp. 390-396.
Berg, K. and Moan, J. “Lysosomes and Microtubules as Targets for Photochemotherapy of Cancer” (1997)Photochemistry and Photobiology,vol. 65, No. 3, pp. 403-409.
Biolo et al. “Effect of Photosensitizer Delivery System and Irradiation Parameters on the Efficiency of Photodynamic Therapy of B16 Pigmented Melanoma in Mice” (1996)Photochemistry and Photobiology,vol. 63, No. 2, pp. 224-228.
Birchler M et al. “Selective Targeting and Photocoagulation of Ocular Angiogenesis Mediated by a Phage-derived Human antibody Fragment” (1999)Nature Biotechnology,vol. 17, No. 10, pp. 984-988.
Brem et al. “The Combination of Antiangiogenic Agents to Inhibit Primary Tumor Growth and Metastasis” (1993)J. Ped. Surgery,vol. 28, No. 10, pp. 1253-1257.
Bressler, et al. “Age-related Macular Degeneration” (1998)Survey of Ophthalmology,vol. 32, No. 6, pp. 375-413.
Brooks et al. “Integrin ανβ3Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels” (1994)Cell,vol. 79, pp. 1157-1164.
Brooks et al. “Requirement of Vascular Integrin ανβ3for Angiogenesis” (1994)Science,vol. 264, pp. 569-571.
Ciardiello et al. “Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A” (1996)J. Natl. Can. Inst.,vol. 88, No. 23, pp. 1770-1776.
Ciulla T A et al. “Changing Therapeutic Paradigms for Exudative Age-related Macular Degeneration: Antiangiogenic Agents and Photodynamic Therapy” (1999)Expert Opinion on Investigational Drugs, Ashley Publications LTD,vol. 8, No. 12, pp. 2173-2182.
D'Amato et al. “Thalidomide is an Inhibitor of Angiogenesis” (1994)Proc. Natl. Acad. Sci. USA,vol. 91, pp. 4082-4085.
Dimitroff C J et al. “Anti-Angiogenic Activity Of Selected Receptor Tyrosine Kinase Inhibitors, PD166285 And PD173074: Implications For Combination Treatment With Photodynamic Therapy” (1999)Investigational New Drugs,vol. 17, No. 2, pp. 121-135.
Dobi et al. “A New Model of Experimental Choroidal Neovascularization in the Rat” (1989)Arch Ophthalmol,vol. 107, pp. 264-269.
Dougherty et al. “Photodynamic Therapy” (1998)J. Natl. Can. Inst.,vol. 90, No. 12, pp. 889-905.
Ellerby et al. “Anti-cancer activity of targeted pro-apoptotic peptides” (1999)Nature Medicine,vol. 5, No. 9, pp. 1032-1038.
Ferrario et al. “Antiangiogenic Treatment Enhances Photodynamic Therapy Responsiveness in a Mouse Mammary Carcinoma” (2000)Cancer Research,vol. 60, No. 15, pp. 4066-4069.
Fingar et al. “Analysis of Acute Vascular Damage After Photodynamic Therapy Using Benzoporphyrin Derivative (BPD)” (1999)British Journal of Cancer,vol. 79, pp. 1702-1708.
Folkman, J. “Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease” (1995)Nature Medicine,vol. 1, pp. 27-31.
Friedlander et al. “Definition of Two Angiogenic Pathways by Distinct ανIntegrins”(1995)Science,vol. 270, pp. 1500-1502.
Friedlander et al. “Involvement of Integrins ανβ3and ανβ5in Ocular Neovascular Diseases” (1996)Pro. Natl. Acad. Sci. USA,vol. 93, pp. 9764-9769.
Granville et al. “Overexpression of Bcl-XLPrevents Caspase-3-mediated Activation of DNA Fragmentation Factor (DFF) Produced by Treatment with the Photochemotherapeutic Agent BPD-MA” (1998)FEBS Letters,vol. 422, pp. 151-154.
Granville et al. “Rapid cytochromecRelease, Activation of Caspases 3, 6, 7 and 8 Followed by Bap31 Cleavage in HeLa cells Treated with Photodynamic Therapy” (1998)FEBS Letters,vol. 437, pp. 5-10.
Gupta et al. “Involvement of Nitric Oxide During Phthalocyanine (Pc4) Photodynamic Therepy-Mediated Apoptosis” (1998)Cancer Research,vol. 58, pp. 1785-1788.
Guyer et al. “Subfoveal Choroidal Neovascular Membranes in Age-Related Macular Degeneration” (1986)Arch Ophthalmol,vol. 104, pp. 702-705.
Hakem et al. “Differential Requirement for Caspase 9 in Apoptotic Pathways in Vivo” (1998)Cell,vol. 94, pp. 339-352.
Hanahan, D. and Folkman, J. “Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis” (1996)Cell,vol. 86, pp. 353-364.
He et al. “Photodynamic Therapy with Photofrin II Induces Programmed Cell Death in Carcinoma Cell Lines” (1994)Photochemistry and Photobiology,vol. 59, No. 4, pp. 468-473.
He et al. “The Induction of Partial Resistance to Photodynamic Therapy by the ProtooncogeneBCL-2” (1996)Photochemistry and Photobiology,vol. 64, No. 5, pp. 845-852.
He et al. “Variation in Photodyna
Gragoudas Evangelos S.
Miller Joan W.
Renno Reem Z.
Chan Christina
Goodwin & Procter LLP
Huynh Phuong
Massachusetts Eye and Ear Infirmary
LandOfFree
Methods and compositions for treating conditions of the eye does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating conditions of the eye, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating conditions of the eye will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3640659